This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
« Back
Page 1 of 2

Options Trade Into Ziopharm's Sarcoma Drug Study Results

By Tony Pelz

Options expert Tony Pelz says options are the best way to trade Ziopharma's looming palifosamide data.

11:00AM 02/26/13

Dynavax Options Trade for Heplisav FDA Approval Decision

By Tony Pelz

Options expert Tony Pelz offers investors a way to use options to trade Dynavax's upcoming FDA decision.

08:30AM 02/12/13

Alexza Pharma: Premium Selling Options Strategy

By Tony Pelz

A new options trade for Alexza going into an FDA drug approval decision.

11:27AM 12/12/12

Amicus: Bullish Options Trade Into Clinical Trial Catalysts

By Tony Pelz

Contributor Tony Pelz offers an options trade for those who believe Amicus shares are going higher.

09:05AM 12/04/12

Dynavax: Speculative Upside Options Trade

By Tony Pelz

How to use options to play a possible run-up in Dynavax prior to the FDA's approval decision.

07:31AM 11/20/12

Exelixis: New Drug Approval Options Trade

By Tony Pelz

Options wizard Tony Pelz suggests another way to trade Exelixis's FDA drug approval decision.

08:00AM 11/06/12

Eli Lilly: Bearish Options Trade

By Tony Pelz

Tony Pelz offers a short-term options trade to take advantage of end-of-year selling in Eli Lilly.

10:01AM 11/01/12

Ziopharm: Options Trade for Phase III Data

By Tony Pelz

How to play the high-risk release of results from Ziopharm's phase III study.

08:30AM 10/22/12

How to Hedge Profits in Sarepta Therapeutics

By Tony Pelz

Options guru Tony Pelz offers options trades for those who want to protect their Sarepta profits.

09:00AM 10/15/12

NPS Pharma: Bullish Options Trade Into the Gattex FDA Panel

By Tony Pelz

Biotech options expert Tony Pelz recommends a bullish options trade for the Oct. 16 Gattex FDA panel.

08:00AM 10/08/12

« Back
Page 1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,234.71 -51.03 -0.28%
S&P 500 2,128.45 -2.37 -0.11%
NASDAQ 5,091.3550 +0.5610 0.01%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs